Alignment Healthcare (ALHC) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.16 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +67.04%. A quarter ago, it was expected that this Medicare Advantage insurer would post a loss of $0.07 per share when it actually produced earnings of $0.02, delivering a surprise of +128.57%.Over the last four qua ...

Core Insights - Investors have withdrawn hundreds of billions of dollars from software stocks following the release of an AI tool by Anthropic that automates legal work, significantly impacting the legal software sector [1] - Software stocks have declined by 18% this year, with estimated losses in the sector exceeding US$1 trillion when considering market capitalization, bonds, and loans [1] - The shift in investor focus towards blue-chip companies indicates the beginning of AI's transformative impact on the investment landscape [1] Company-Specific Developments - Celestica Inc. (CLS:TSX) saw its stock rise nearly 10%, making it one of the top gainers, with analysts from TD Cowen maintaining a price target of $451 due to its connections with Google's AI initiatives [1] - Desjardins Group Capital Markets analysts have reduced their price targets for several TSX tech companies, including Constellation Software Inc. (CSU:TSX) from $5,300 to $3,900, with shares trading at $2,380 [1] - Price targets for Topicus.com Inc. were cut from $190 to $140, and for Lumine Group Inc. from $52 to $36, with shares closing at $94.72 and $20.00 respectively [1] Industry Trends - The decline in software stocks is attributed to the perception that AI may replace existing business models rather than a traditional market bubble burst [1] - Major U.S. software companies such as ServiceNow Inc., Salesforce Inc., Intuit Inc., and Oracle Corp. have experienced stock declines ranging from 20% to 30% year to date [1]

Core Insights - M33 Growth has partnered with U.S. Neurology Associates (USNA) to enhance community-based neurology care [1][2] - Nitin Jain has been appointed as CEO of USNA, with Brad Hively as Chairman and co-founder [1] - The partnership aims to leverage innovative diagnostics and treatments to improve patient care in neurology [2][3] Company Overview - U.S. Neurology Associates (USNA) is focused on transforming neurology practices by providing comprehensive and coordinated care [2][5] - USNA aims to alleviate operational challenges for physicians, allowing them to concentrate on patient care [3] - The organization is committed to improving access, operational excellence, and clinical innovation in neurology practices across the U.S. [5] Industry Context - Neurology is experiencing a significant increase in patients with chronic conditions requiring long-term treatment [2] - The current delivery of neurological care is at an inflection point, with opportunities to integrate technology and clinical quality [3] - USNA recognizes the high costs associated with specialty care and aims to provide cost-effective solutions through integrated community clinics [3]

Core Insights - The Oncology Institute, Inc. (TOI) has shown signs of imminent profitability, with a notable 37% improvement reported in its 3Q25 results, leading to a rally in its shares since November 14, 2025 [2]. Company Summary - TOI specializes in cancer care and cost management solutions, indicating a focus on addressing both treatment and financial aspects of cancer care [2]. - The company is part of a model portfolio that includes 12-20 high upside biotech stocks, suggesting a strategic approach to investment in the biotech sector [2].

Core Insights - Several small- and mid-cap stocks experienced notable gains in after-hours trading, driven by investor sentiment and sector momentum rather than new company news [1][2][3][4][5] Company Summaries - **Spyre Therapeutics, Inc. (SYRE)**: Closed at $34.71, up $1.65 or 4.99%, leading the list of gainers despite no new updates [1] - **The Oncology Institute, Inc. (TOI)**: Ended at $3.65, up $0.19 or 5.49%, with steady share price increase without new announcements [2] - **Aurora Cannabis Inc. (ACB)**: Closed at $5.70, gaining $0.13 or 2.33%, benefiting from renewed momentum in the cannabis sector [2] - **Solid Biosciences Inc. (SLDB)**: Finished at $5.45, up $0.07 or 1.30%, supported by the recent addition of Duchenne muscular dystrophy to the Recommended Uniform Screening Panel [3] - **EUDA Health Holdings Limited (EUDA)**: Closed at $2.74, gaining $0.12 or 4.58%, attracting buyers in after-hours trading [4] - **Lexeo Therapeutics, Inc. (LXEO)**: Ended at $9.50, up $0.39 or 4.28%, continuing a trend of strength in the biotech sector [4] - **Eledon Pharmaceuticals, Inc. (ELDN)**: Closed at $1.59, up $0.02 or 1.27%, managing a modest gain without new news [5]

Group 1: Elastic NV Performance - Elastic NV reported second-quarter adjusted earnings of 64 cents per share, exceeding the analyst estimate of 58 cents [1] - The company's quarterly revenue was $423.48 million, surpassing the Street estimate of $418.16 million [1] - Despite the positive earnings and revenue results, Elastic shares fell 12.3% to $72.02 in pre-market trading [1] Group 2: Other Stocks in Pre-Market Trading - Luda Technology Group Ltd experienced an 11.1% decline to $8.55 after a 39% gain on Thursday [4] - AnaptysBio Inc fell 9.7% to $34.00 following the announcement of a $100 million stock repurchase plan [4] - Sigma Lithium Corp decreased by 8.4% to $8.61 after a 9% decline on Thursday [4] - Veeva Systems Inc saw a 6.7% drop to $252.40 despite posting upbeat third-quarter results and raising fiscal year earnings and revenue estimates [4] - American Bitcoin Corp declined 6.3% to $4.29 in pre-market trading [4] - Standard Lithium Ltd fell 6.3% to $3.60 [4] - Indivior PLC declined 5.9% to $29.90 after settling a matter with the U.S. Department of Justice for $295 million [4] - HIVE Digital Technologies Ltd dropped 5.8% to $2.75 after filing for mixed shelf [4] - Albemarle Corp fell 5.5% to $109.99 [4] - Oncology Institute Inc decreased by 2.1% to $3.17 [4]

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential opportunities for traders before the market opens [1] Premarket Gainers - Cidara Therapeutics, Inc. (CDTX) is up 91% at $203.18 - Binah Capital Group, Inc. (BCG) is up 45% at $2.07 - Invivyd, Inc. (IVVD) is up 42% at $2.52 - Omeros Corporation (OMER) is up 15% at $7.25 - The Oncology Institute, Inc. (TOI) is up 12% at $3.47 - AlphaVest Acquisition Corp (ATMV) is up 11% at $7.99 - ARB IOT Group Limited (ARBB) is up 7% at $7.31 - Hyperion DeFi, Inc. (HYPD) is up 6% at $5.27 - TruGolf Holdings, Inc. (TRUG) is up 6% at $2.02 - Boqii Holding Limited (BQ) is up 5% at $2.24 [3] Premarket Losers - TSS, Inc. (TSSI) is down 40% at $9.12 - StubHub Holdings, Inc. (STUB) is down 20% at $15.02 - ESS Tech, Inc. (GWH) is down 20% at $3.38 - Red Cat Holdings, Inc. (RCAT) is down 17% at $6.38 - WhiteFiber, Inc. (WYFI) is down 15% at $16.81 - New Era Energy & Digital, Inc. (NUAI) is down 13% at $3.66 - NET Power Inc. (NPWR) is down 11% at $2.62 - Korro Bio, Inc. (KRRO) is down 9% at $5.90 - Anavex Life Sciences Corp. (AVXL) is down 8% at $5.20 - Interactive Strength Inc. (TRNR) is down 5% at $2.47 [4]

Core Insights - Biorestorative Therapies, Inc. (BRTX) reported a quarterly loss of $0.38 per share, consistent with the Zacks Consensus Estimate, compared to a loss of $0.13 per share a year ago [1] - The company posted revenues of $0.01 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 97%, and down from $0.23 million year-over-year [2] - Biorestorative Therapies shares have declined approximately 1.4% year-to-date, while the S&P 500 has gained 16.4% [3] Financial Performance - The company has surpassed consensus EPS estimates two times over the last four quarters [1] - The current consensus EPS estimate for the upcoming quarter is -$0.28 on revenues of $0.5 million, and for the current fiscal year, it is -$1.55 on revenues of $1.23 million [7] Market Outlook - The earnings outlook and estimate revisions will significantly influence the stock's price movement [4] - The Zacks Rank for Biorestorative Therapies is currently 3 (Hold), indicating expected performance in line with the market [6] - The Medical - Biomedical and Genetics industry is ranked in the top 34% of over 250 Zacks industries, suggesting a favorable industry outlook [8]

Core Insights - Establishment Labs Holdings Inc. reported a quarterly loss of $0.38 per share, which was better than the Zacks Consensus Estimate of a loss of $0.54, marking an earnings surprise of +29.63% [1] - The company generated revenues of $53.78 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 3.45% and showing a year-over-year increase from $40.23 million [2] - The stock has underperformed the market with a gain of about 7.2% since the beginning of the year, compared to the S&P 500's gain of 15.1% [3] Financial Performance - Over the last four quarters, Establishment Labs has surpassed consensus EPS estimates two times [2] - The current consensus EPS estimate for the upcoming quarter is -$0.36 on revenues of $64.57 million, and for the current fiscal year, it is -$2.09 on revenues of $209.24 million [7] Industry Outlook - The Medical Services industry, to which Establishment Labs belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, indicating potential challenges ahead [8] - The performance of Establishment Labs' stock may be influenced by the overall outlook of the industry [8]

Core Insights - CryoPort, Inc. reported a quarterly loss of $0.18 per share, better than the Zacks Consensus Estimate of a loss of $0.23, representing an earnings surprise of +21.74% [1] - The company posted revenues of $44.23 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 8.32%, although this is a decline from $56.66 million in the same quarter last year [2] - CryoPort shares have increased by approximately 16.2% year-to-date, slightly underperforming the S&P 500's gain of 16.5% [3] Earnings Outlook - The earnings outlook for CryoPort is mixed, with the current consensus EPS estimate for the upcoming quarter at -$0.20 on revenues of $43.17 million, and -$0.85 on revenues of $170.5 million for the current fiscal year [7] - The company's Zacks Rank is currently 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Medical Services industry, to which CryoPort belongs, is currently ranked in the bottom 43% of over 250 Zacks industries, suggesting potential challenges ahead [8] - The Oncology Institute, Inc., another company in the same industry, is expected to report a quarterly loss of $0.12 per share, with revenues projected to be $122.25 million, reflecting a year-over-year increase of 22.4% [9][10]